Organization | BioEq

BioEq Report issue

For profit Phase 1 Phase 3

Founded: St. Petersburg Russian Federation (2012)

Status: No NME R&D (2012)

Organization Overview

First Clinical Trial

2014

NCT02359877

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Bioeq GmbH | Limited Liability Company "BioEk" Ltd. | LLC BioEk | OOO BioEk

Active Ingredients

Drugs in Phase 3 Trials (8)

aflibercept (zaltrap) (1 trial)

inosine (2 trials)

methionine (2 trials)

nicotinamide (2 trials)

ranibizumab (lucentis) (1 trial)

ringer's lactate (2 trials)

sodium succinate (3 trials)

ustekinumab (stelara) (1 trial)

Drugs in Phase 1 Trials (3)

bcd-135 (1 trial)

interferon beta-1b (betaseron) (1 trial)

peginterferon beta-1a (Plegridy) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Renal Cell (Phase 1)

Fatty Liver (Phase 2)

Jaundice (Phase 3)

Jaundice, Obstructive (Phase 3)

Liver Diseases (Phase 2)

Macular Degeneration (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Psoriasis (Phase 3)

Wet Macular Degeneration (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 8
# of Trial APIs: 11